Patent Assignment
Reel/Frame 068748/0873
Security Interest
Recorded: 2024-08-22
Pages: 22
Assignor
EPIC SCIENCES, INC.
Executed: 2024-06-26
Assignee
LABORATORY CORPORATION OF AMERICA HOLDINGS
531 SOUTH SPRING ST., BURLINGTON, NORTH CAROLINA, 27215
Covered Properties
(79)
Method for Optimizing the Collection of Rare Cells in Blood
Application:
61/540,323 →
Applications of Single Cell Omics
Application:
61/435,721 →
Methods for Obtaining Single Cells
Application:
61/435,704 →
Single Cell Omics
Application:
61/435,724 →
Methods for Obtaining Single Cells and Applications of Single Cell Omics
Application:
14/001,154 →
Publication:
US 2014/0308669
Methods for the Detection and Quantification of Circulating Tumor Cell Mimics
Application:
61/934,600 →
Methods for the Detection and Quantification of Circulating Tumor Cell Mimics
Application:
15/115,225 →
Publication:
US 2016/0341732
Methods for Analyzing Rare Circulating Cells
Application:
61/943,192 →
Ck- and Small Nuclear Size Circulating Tumor Cell (Ctc) Phenotypes in Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
Application:
61/932,096 →
Methods for the Detection and Quantification of Circulating Endothelial Cells
Application:
61/913,722 →
Methods for the Detection and Quantification of Circulating Endothelial Cells
Application:
15/103,027 →
Publication:
US 2016/0305958
Circulating Tumor Cell Diagnostics for Lung Cancer
Application:
61/921,694 →
Circulating Tumor Cell Diagnostics for Lung Cancer
Application:
14/581,968 →
Publication:
US 2015/0185204
Compositions and Methods for Fluid Biopsy of Melanoma
Application:
61/991,088 →
Compositions and Methods for Fluid Biopsy of Melanoma
Application:
15/309,412 →
Publication:
US 2017/0192003
Heterogeneity of Prostate Specific Membrane Antigen (Psma) Expression in Traditional and Apoptotic Circulating Tumor Cells (Ctc) in Metastatic Castration Resistant Prostate Cancer (Mcrpc)
Application:
61/932,117 →
MOLECULAR CHARACTERIZATION OF CIRCULATING TUMOR CELLS (CTCs) OF NEUROENDOCRINE PROSTATE CANCER (NEPC) PATIENTS
Application:
61/932,172 →
Circulating Tumor Cell Diagnostics for Detection of Neuroendocrine Prostate Cancer (Nepc)
Application:
14/605,809 →
Publication:
US 2016/0040245
Heterogeneity of Prostate Specific Membrane Antigen (Psma) Expression in Traditional and Apoptotic Circulating Tumor Cells (Ctc) in Metastatic Castration Resistant Prostate Cancer (Mcrpc)
Application:
61/933,771 →
Detection of Prostate Specific Membrane Antigen (Psma) Expression on Circulating Tumor Cells (Ctc)
Application:
14/605,913 →
Publication:
US 2016/0011198
Molecular Characterization of Circulating Tumor Cells (Ctc) and Ctc Subpopulations in Progressive Metastatic Castration Resistant Prostate Cancer (Mcrpc)
Application:
61/933,774 →
Circulating Tumor Cell Diagnostics for Biomarkers Predictive of Resistance to Androgen Receptor (Ar) Targeted Therapies
Application:
14/609,356 →
Publication:
US 2015/0212089
Method of Using Non-Circulating Tumor Cells to Detect Circulating Tumor Cells
Application:
61/253,787 →
Method of Using Non-Rare Cells to Detect Rare Cells
Application:
13/503,014 →
Publication:
US 2012/0276555
Methods for the Detection of Circulating Tumor Cells
Application:
13/897,136 →
Publication:
US 2013/0252259
Method for Categorizing Circulating Tumor Cells
Application:
13/393,177 →
Publication:
US 2012/0178094
Apparatus, System and Method for Identifying Circulating Tumor Cells
Application:
14/363,290 →
Publication:
US 2014/0329917
Circulating Tumor Cell Diagnostics for Therapy Targeting Pd-L1
Application:
62/064,320 →
Circulating Tumor Cell Diagnostics for Therapy Targeting Pd-L1
Application:
15/519,129 →
Publication:
US 2017/0242016
Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
Application:
15/024,483 →
Publication:
US 2016/0266127
Circulating Tumor Cell Diagnostics for Identification of Resistance to Androgen Receptor Targeted Therapies
Application:
62/055,491 →
Circulating Tumor Cell Diagnostics for Identification of Resistance to Androgen Receptor Targeted Therapies
Application:
15/513,915 →
Publication:
US 2017/0285035
Method for Categorizing Circulating Tumor Cells
Application:
14/678,415 →
Publication:
US 2015/0212091
Intra-Patient Genomic Heterogeneity of Single Circulating Tumor Cells (Ctcs) Associated to Phenotypic Ctc Heterogeneity in Metastatic Castrate Resistant Prostate Cancer (Mcrpc)
Application:
62/168,607 →
Intra-Patient Genomic Heterogeneity of Single Circulating Tumor Cells (Ctcs) Associated to Phenotypic Ctc Heterogeneity in Metastatic Castrate Resistant Prostate Cancer (Mcrpc)
Application:
15/577,307 →
Publication:
US 2018/0155794
ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)
Application:
62/233,206 →
ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)
Application:
15/762,076 →
Publication:
US 2019/0285636
SINGLE CELL GENOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCs) IN METASTATIC DISEASE TO CHARACTERIZE DISEASE HETEROGENEITY
Application:
62/250,422 →
Single Cell Genomic Profiling of Circulating Tumor Cells (Ctcs) in Metastatic Disease to Characterize Disease Heterogeneity
Application:
15/773,154 →
Publication:
US 2018/0321247
SINGLE CELL GENOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCs) IN METASTATIC DISEASE TO CHARACTERIZE DISEASE HETEROGENEITY
Application:
62/275,659 →
SINGLE CELL GENOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCs) IN METASTATIC DISEASE TO CHARACTERIZE DISEASE HETEROGENEITY
Application:
62/344,703 →
Single Cell Genomic Profiling of Circulating Tumor Cells (Ctcs) in Metastatic Disease to Characterize Disease Heterogeneity
Application:
16/068,348 →
Publication:
US 2019/0025312
Circulating Tumor Cell Diagnostics for Biomarkers Predictive of Resistance to Androgen Receptor (Ar) Targeted Therapies
Application:
15/478,002 →
Publication:
US 2018/0052167
Method of Using Non-Rare Cells to Detect Rare Cells
Application:
15/601,696 →
Publication:
US 2018/0100857
Methods of Determining Therapies Based on Single Cell Characterization of Circulating Tumor Cells (Ctcs) in Metastatic Disease
Application:
62/514,642 →
Methods of Determining Therapies Based on Single Cell Characterization of Circulating Tumor Cells (Ctcs) in Metastatic Disease
Application:
62/531,725 →
Methods of Determining Therapies Based on Single Cell Characterization of Circulating Tumor Cells (Ctcs) in Metastatic Disease
Application:
16/617,423 →
Publication:
US 2022/0260574
Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in a Mammalian Subject
Application:
15/710,102 →
Publication:
US 2018/0196049
Circulating Tumor Cell Diagnostics for Prostate Cancer Biomarkers
Application:
16/691,461 →
Publication:
US 2020/0333345
Methods of Using Non-Rare Cells to Detect Rare Cells
Application:
16/819,684 →
Publication:
US 2021/0033612
Circulating Tumor Cell Diagnostics for Lung Cancer
Application:
16/885,028 →
Publication:
US 2021/0109086
Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
Application:
16/884,737 →
Publication:
US 2021/0109101
Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in a Mammalian Subject
Application:
16/992,232 →
Publication:
US 2021/0190783
Single Cell Genomic Profiling of Circulating Tumor Cells (Ctcs) in Metastatic Disease to Characterize Disease Heterogeneity
Application:
17/142,767 →
Publication:
US 2021/0405055
Compositions and Methods for Fluid Biopsy of Melanoma
Application:
17/160,171 →
Publication:
US 2021/0396757
Methods for the Detection and Quantification of Circulating Tumor Cell Mimics
Application:
17/142,662 →
Publication:
US 2021/0373026
Detection of Prostate Specific Membrane Antigen (Psma) Expression on Circulating Tumor Cells (Ctc)
Application:
17/170,769 →
Publication:
US 2021/0382057
Circulating Tumor Cell Diagnostics for Identification of Resistance to Androgen Receptor Targeted Therapies
Application:
17/323,912 →
Publication:
US 2022/0091123
Circulating Tumor Cell Diagnostics for Biomarkers Predictive of Resistance to Androgen Receptor (Ar) Targeted Therapies
Application:
17/323,976 →
Publication:
US 2022/0091124
Intra-Patient Genomic Heterogeneity of Single Circulating Tumor Cells (Ctcs) Associated to Phenotypic Ctc Heterogeneity in Metastatic Castrate Resistant Prostate Cancer (Mcrpc)
Application:
17/377,074 →
Publication:
US 2022/0162706
Methods for the Detection and Quantification of Circulating Endothelial Cells
Application:
17/398,846 →
Publication:
US 2022/0187311
Single Cell Genomic Profiling of Circulating Tumor Cells (Ctcs) in Metastatic Disease to Characterize Disease Heterogeneity
Application:
17/579,437 →
Publication:
US 2022/0390451
Circulating Tumor Cell Diagnostics for Detection of Neuroendocrine Prostate Cancer (Nepc)
Application:
17/700,146 →
Publication:
US 2023/0033449
Method of Using Non-Rare Cells to Detect Rare Cells
Application:
17/746,756 →
Publication:
US 2023/0085158
Circulating Tumor Cell Diagnostics for Lung Cancer
Application:
18/048,759 →
Publication:
US 2023/0304993
ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)
Application:
18/175,427 →
Publication:
US 2024/0036047
Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
Application:
18/174,015 →
Publication:
US 2024/0027458
Detection of Prostate Specific Membrane Antigen (Psma) Expression on Circulating Tumor Cells (Ctc)
Application:
18/308,579 →
Publication:
US 2024/0103003
Circulating Tumor Cell Diagnostics for Biomarkers Predictive of Resistance to Androgen Receptor (Ar) Targeted Therapies
Application:
18/495,585 →
Publication:
US 2024/0319193
Methods for the Detection and Quantification of Circulating Tumor Cell Mimics
Application:
18/676,257 →
Publication:
US 2025/0130236
Enhanced Characterization of Breast Cancer
Application:
18/076,945 →
Publication:
US 2023/0175073
Compositions and Methods for Prostate Cancer Analysis
Application:
15/789,768 →
Publication:
US 2018/0209982
Compositions and Methods for Prostate Cancer Analysis
Application:
16/721,108 →
Publication:
US 2020/0200752
Methods for Detecting 5T4-Positive Circulating Tumor Cells and Methods of Diagnosis of 5T4-Positive Cancer in a Mammalian Subject
Methods for Analyzing Rare Circulating Cells
Circulating Tumor Cell Diagnostics for Prostate Cancer Biomarkers
Methods for the Detection of Circulating Tumor Cells
Method of Using Non-Rare Cells to Detect Rare Cells
Methods for Analyzing Rare Circulating Cells
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 5, 2010
From: KUHN, PETER; KOLATKAR, ANAND; KUNKEN, JOSHUA; MARRINUCCI, DENA
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 023734/0746 →
Assignment of Assignor's Interest
Mar 26, 2012
From: KUHN, PETER
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 027930/0342 →
Assignment of Assignor's Interest
Jul 20, 2012
From: KUHN, PETER; KOLATKAR, ANAND; KUNKEN, JOSHUA; MARRINUCCI, DENA
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 028603/0253 →
Assignment of Assignor's Interest
Jul 20, 2012
From: STUELPNAGEL, JOHN R.
To: EPIC SCIENCES, INC.
Reel/Frame 028603/0101 →
Assignment of Assignor's Interest
Nov 13, 2014
From: DITTAMORE, RYAN
To: EPIC SCIENCES, INC.
Reel/Frame 034168/0265 →
Assignment of Assignor's Interest
Nov 13, 2014
From: DITTAMORE, RYAN
To: EPIC SCIENCES, INC.
Reel/Frame 034168/0660 →
Assignment of Assignor's Interest
Nov 13, 2014
From: DITTAMORE, RYAN
To: EPIC SCIENCES, INC.
Reel/Frame 034168/0509 →
Assignment of Assignor's Interest
Nov 14, 2014
From: DITTAMORE, RYAN
To: EPIC SCIENCES, INC.
Reel/Frame 034178/0877 →
Assignment of Assignor's Interest
Nov 14, 2014
From: DITTAMORE, RYAN
To: EPIC SCIENCES, INC.
Reel/Frame 034179/0007 →
Assignment of Assignor's Interest
Dec 30, 2014
From: DITTAMORE, RYAN
To: EPIC SCIENCES, INC.
Reel/Frame 034604/0039 →
Assignment of Assignor's Interest
Dec 31, 2014
From: MARRINUCCI, DENA
To: EPIC SCIENCES, INC.
Reel/Frame 034607/0848 →
Assignment of Assignor's Interest
Jan 2, 2015
From: DITTAMORE, RYAN
To: EPIC SCIENCES, INC.
Reel/Frame 034621/0586 →
Assignment of Assignor's Interest
Jan 2, 2015
From: KUHN, PETER
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 034614/0382 →
Assignment of Assignor's Interest
Jan 5, 2015
From: DITTAMORE, RYAN
To: EPIC SCIENCES, INC.
Reel/Frame 034636/0797 →
Assignment of Assignor's Interest
Mar 23, 2015
From: DITTAMORE, RYAN
To: EPIC SCIENCES, INC.
Reel/Frame 035235/0100 →
Assignment of Assignor's Interest
Mar 23, 2015
From: DITTAMORE, RYAN
To: EPIC SCIENCES, INC.
Reel/Frame 035235/0031 →
Assignment of Assignor's Interest
Mar 23, 2015
From: DITTAMORE, RYAN
To: EPIC SCIENCES, INC.
Reel/Frame 035234/0620 →
Assignment of Assignor's Interest
May 8, 2015
From: VELASCO, CARMEN RUIZ
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 035597/0252 →
Assignment of Assignor's Interest
Jul 20, 2015
From: NAIR, VISWAM S.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 036138/0108 →
Assignment of Assignor's Interest
Jul 20, 2015
From: KUHN, PETER; CARLSSON, ANDERS; KOLATKAR, ANAND
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 036138/0067 →
Assignment of Assignor's Interest
Jul 20, 2015
From: GAMBHIR, SANJIV SAM
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 036138/0160 →
Assignment of Assignor's Interest
Oct 21, 2015
From: DITTAMORE, RYAN; LANDERS, MARK
To: EPIC SCIENCES, INC.
Reel/Frame 036849/0788 →
Confirmatory License
Oct 23, 2015
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036944/0671 →
Assignment of Assignor's Interest
Jul 20, 2016
From: KUHN, PETER; CARLSSON, ANDERS; KOLATKAR, ANAND
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 039403/0192 →
Assignment of Assignor's Interest
Jul 20, 2016
From: NAIR, VISWAM S.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 039198/0555 →